破伤风疫苗商业化加速,康希诺与远大生命科学签署独家合作协议

时代财经
21 Mar

本文来源:时代财经3月21日,康希诺和远大生命科学集团有限公司(简称“远大生命科学”)共同宣布,就吸附破伤风疫苗达成独家商业化合作协议。根据协议约定,康希诺生物将授权给远大生命科学就公司研发的吸附破伤风疫苗在产品获批后,在大中华区进行独家推广服务,进一步扩大疫苗可及性。而康希诺将获得首付款、产品获批上市及产品超过特定收入的里程碑付款,自协议签署起的十年内累计可达一亿元。同时,公司会根据推广销售额向...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10